中基健康(000972) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached ¥149,986,679.55, a significant increase of 502.91% compared to ¥24,877,144.60 in the same period last year[4] - Net profit attributable to shareholders was ¥16,882,477.46, a turnaround from a loss of ¥4,986,755.44 in the previous year[4] - The total operating revenue for Q1 2023 was CNY 149,986,679.55, a significant increase from CNY 24,893,658.36 in the same period last year, representing a growth of approximately 502.5%[18] - The operating income for Q1 2023 was CNY 149,986,679.55, up from CNY 24,877,144.60 in the previous year, reflecting a growth of approximately 502.5%[18] - The company reported a net loss of CNY 1,767,177,601.07, slightly improved from a loss of CNY 1,784,060,078.53 in the previous period[16] - The company's net profit for Q1 2023 reached CNY 16,854,769.66, a significant recovery from a net loss of CNY 4,995,605.10 in the same period last year, marking a turnaround of over 436%[19] - Operating profit for the quarter was CNY 16,965,309.28, compared to an operating loss of CNY 5,017,714.54 in Q1 2022, indicating a strong operational performance improvement[19] - The company reported basic and diluted earnings per share of CNY 0.0219, recovering from a loss per share of CNY -0.0065 in Q1 2022[19] Cash Flow and Liquidity - The net cash flow from operating activities increased by 47.52% to ¥63,401,042.48 from ¥42,976,551.37 year-on-year[4] - Cash flow from operating activities generated a net inflow of CNY 63,401,042.48, up from CNY 42,976,551.37 in the previous year, reflecting a growth of approximately 47%[20] - The cash and cash equivalents at the end of Q1 2023 were CNY 249,557,422.61, an increase from CNY 207,471,741.60 at the beginning of the year, showing a growth of about 20.3%[14] - The cash and cash equivalents at the end of the period totaled CNY 249,557,422.61, compared to CNY 63,204,247.88 at the end of Q1 2022, showing a significant increase of approximately 295%[21] Assets and Liabilities - Total assets decreased by 9.40% to ¥747,759,865.77 from ¥825,364,850.66 at the end of the previous year[4] - Total assets as of March 31, 2023, were CNY 747,759,865.77, down from CNY 825,364,850.66 at the beginning of the year, reflecting a decrease of approximately 9.4%[16] - Total liabilities decreased to CNY 630,484,002.22 from CNY 724,943,756.77, a reduction of about 12.9%[16] - The total equity attributable to shareholders of the parent company increased to CNY 112,196,664.15 from CNY 95,314,186.69, representing a growth of approximately 17.7%[16] Operational Efficiency - Accounts receivable decreased by 64.70% to ¥31,245,338.31, reflecting effective collection of previous sales[8] - Accounts receivable decreased to CNY 31,245,338.31 from CNY 88,520,062.41, a reduction of approximately 64.7%[14] - Inventory decreased by 42.03% to ¥125,654,535.42 due to seasonal production and sales[8] - Inventory levels decreased to CNY 125,654,535.42 from CNY 216,762,597.82, indicating a decline of about 42.1%[15] Expenses and Investments - The total operating costs for Q1 2023 amounted to CNY 134,587,988.45, compared to CNY 30,042,866.00 in Q1 2022, indicating an increase of about 348.5%[18] - The company incurred total expenses of CNY 127,165,385.99 in operating activities, compared to CNY 23,662,896.48 in the same period last year, indicating a rise in operational costs[20] - The company made a long-term equity investment of ¥4,000,000.00 during the quarter, indicating strategic expansion efforts[9] - The company reported a significant increase in sales expenses by 874.70% to ¥1,370,036.82, driven by higher sales volume[9] Government Support and R&D - The company received government subsidies amounting to ¥100,723.82, contributing to other income[7] - The company has not reported any research and development expenses for the quarter, indicating a potential area for future investment[19] - The company has not disclosed any new product developments or market expansion strategies in this report, suggesting a focus on consolidating current operations[19]